QOL after bladder cancer treatment vs other cancersMay 28th 2021
"This study provides important and clinically useful information that can be used to plan the intensity of treatment and counsel our patients regarding the cancer-related and QOL-related outcomes after treatment," writes Badar M. Mian, MD.
FDA grants priority review to nivolumab as adjuvant treatment for muscle-invasive urothelial carcinomaApril 30th 2021
The agency made the designation on the basis of recently reported data from the phase 3 CheckMate 274 trial that found a statistically significant improvement in disease-free survival in patients treated with the PD-1 inhibitor.
High-TMB predicts immunotherapy response in bladder but not prostate cancerMarch 24th 2021
“This study represents the most comprehensive analysis to date of tumor mutation burden as a biomarker for response to immune checkpoint blockade,” according to lead study author Daniel J. McGrail, PhD.